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Vascular smooth muscle cells (VSMCs) within the media of adult arteries are normally quiescent, proliferate at low indices, and exist in the G 0 phase of the cell cycle ( Figure 1 ). On stimulation by growth factors or after mechanical trauma, VSMCs exit the quiescent stage G 0 and progress through the G 1 and G 1 /S transition of the cell cycle. G 1 progression is regulated by the assembly and phosphorylation of G 1 cyclin/ cyclin-dependent kinase (CDK) complexes, predominantly cyclin D/CDK-4, 6 and cyclin E/CDK-2 in VSMCs. For example, cyclin D is a growth factor sensor whose transcription initiation, assembly, and nuclear transport is mitogendependent. Endogenous inhibitors of the cyclin/CDK complexes are termed the CDK inhibitors (CKIs). 1 Two groups of CKIs are dominant in cardiovascular biology: the CIP/KIP family, which includes p21
Cip1 , p27 Kip1 , and p57 Kip2 , and the  INK4 family, which includes p15  Ink4b , p16  Ink4a , p18  Ink4c , and  p19 Ink4d . Interestingly, the CIP/KIP proteins are important for growth regulation in many cell types, whereas the INK4 proteins are linked to developmental processes and cell transformation.
The G 1 cyclin/CDK and CKI complexes are active within the nucleus and serve essential functions of growth regulation, DNA damage and repair, and apoptosis. The seminal event of the cell cycle is the transition from the G 1 into the S phase, where DNA replication occurs, thus leading to mitosis or cell division. The G 1 /S phase is a tightly regulated series of molecular checks and balances. Cyclin/CDK complexes, on activation by CDK-activating kinase, phosphorylate the retinoblastoma gene product; a hyperphosphorylated retinoblastoma gene product releases several sequestered proteins, including the transcription factor E2F. After the withdrawal of growth factors or under quiescent conditions, cyclin D levels decrease, and free p27 Kip1 effectively blocks the kinase activity of cyclin E/CDK-2 and arrests cells in G 0 . Although many proteins regulating the G 1 /S phase transition have been characterized, the full details of the transition, including the discovery of novel genes and their function, have yet to be elucidated.
A commonly accepted model of the response to arterial injury suggests that growth factors and other endogenous, biologically active agents are released after injury, thereby changing the composition of the extracellular matrix and triggering a proliferation and migration program. 2 VSMCs initially proliferate in the media, migrate from the media into the intima, undergo further rounds of proliferation, and subsequently form the neointima. Growth factor regulation of VSMC proliferation through different signal transduction pathways has been well described. Processes that initiate VSMC migration are also well understood. 3 A central question in vascular biology has been whether cell cycle control and cell migration are linked. Whether the cell cycle regulates cell migration and the mechanisms by which it does so have not been determined or characterized. Mitogenic stimulation of VSMCs initiates cell cycle progression and cell migration. However, cells in the late S or G 2 /M phase do not migrate. 4 There is a window of opportunity in the G 1 to G 1 /S transition where VSMCs are able to migrate in response to mitogenic stimuli. Therefore, proteins like the CKIs that regulate G 1 cell cycle progression are likely candidates to regulate the initiation of migration. p27
Kip1 is one important candidate, given that it is tightly regulated by mitogens. 5 The study by Sun et al 6 in the present issue of Circulation presents important new data regarding a role for p27 Kip1 in regulating VSMC migration, and as such, adds new pieces to the puzzle of the diverse functions of the cell cycle in cardiovascular biology. Previous work by this group and others has demonstrated that rapamycin inhibits VSMC proliferation in vitro and in vivo by blocking the cell cycle at the G 1 /S transition 7, 8 and, furthermore, that rapamycin treatment of VSMCs inhibited platelet-derived growth factorinduced migration in a Boyden chamber. 9 Rapamycin is an antibiotic that prevents growth factor-dependent downregulation of p27 Kip1 through inhibition of the serine/threonine kinase p70 S6K , a mitogen-stimulated kinase. 10 Rapamycin's antiproliferative properties are dependent, in part, on p27 Kip1 ;
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thus,p27
Kip1 is a likely candidate for mediating rapamycin's inhibitory effects on cell migration as well. 7, 11 Sun et al 6 demonstrate that rapamycin inhibits the migration of mouse VSMCs containing p27 Kip1 (p27 Kipϩ/ϩ and p27 Kip1ϩ/-), but not mouse VSMCs lacking p27 Kip1 (p27 Kip1-/-) in 2 different models: a Boyden chamber that measures the migration of VSMCs in vitro and an aortic explant method that indicates the migration of VSMCs in vivo. Interestingly, the inhibition of cell migration by rapamycin was dosedependent in both models. At lower doses of rapamycin (IC 50 , 2 nmol/L in vitro, 4 mg · kg -1 · d -1 in vivo), p27 Kip1 -dependent effects were observed. However, at higher doses of rapamycin (IC 50 , 200 nmol/L in vitro, 9 mg · kg -1 · d -1 in vivo), inhibition of cell migration was observed in the presence and absence of p27 Kip1 , indicating a p27 Kip1 -independent mechanism as well. This observation was confirmed by examining p27 Kip1 -dependent and -independent migration in the presence of a C3 exoenzyme. The C3 exoenzyme inhibits Ras/RhoA proteins, which are steps in the signal transduction pathway from growth factor receptors to actin-myosin assembly and cell migration, and increases p27
Kip1 levels (see Figure 6 in the article by Sun et al 6 ). Again, a C3 exoenzyme inhibited the migration of p27 Kip1ϩ/ϩ but not p27 Kip1-/-VSMCs, suggesting that both rapamycin and C3 exoenzyme inhibit VSMC migration through p27 Kip1 -dependent and -independent pathways. Does p27 Kip1 regulate VSMC migration? This intriguing question raises the issue of whether p27
Kip1 indirectly regulates VSMC migration by blocking G 1 /S transition via an inhibition of cyclin/CDK activity. Or does p27
Kip1 target a novel signal transduction pathway of cyclin/CDK activity? Or does p27 target a novel signal transduction pathway independent of its cell cycle regulatory function? The authors imply the latter; however, the experimental settings they employ do not permit distinction between these 2 possibilities. Although the experiments are performed with synchronized VSMCs that exit quiescent G 0 stage after growth factor stimulation, it should be noted that pretreatment of cells with rapamycin will differentially alter p27
Kip1ϩ/ϩ and p27 Kipϩ/ϩ cells relative to p27 Kip-/-cells and might account, in part, for differences in migration after rapamycin treatment, because wild-type p27
Kipϩ/ϩ and p27 Kip1-/-cells would be in different phases of the cell cycle.
However, the major point to note is that signal transduction pathways downstream of p27 Kip1 link cell cycle progression and cell migration. The signal transduction pathways upstream of p27 Kip1 are only partially understood. VSMCs in the media of arteries are surrounded by different matrix components, such as type I and type III fibrillar collagen. Degradation of the matrix after vascular injury induces changes in actin-myosin assembly and focal adhesion kinases. Koyama et al 12 reported that polymerized type1 collagen fibrils, which are found in intact arteries, upregulate p27
Kip1 through integrin signaling and inhibition of p70
S6k
, whereas monomeric collagen fibrils support VSMC proliferation. These finding suggest that extracellular cues, such as matrix composition, can signal the nucleus, altering the cell cycle. Further studies are required to determine the mechanism of signaling from the cell surface in toward the nucleus and, in turn, from the nucleus to the cell surface that coordinately regulates VSMC migration. For example, cell migration requires cytoskeletal reorganization mediated by mitogen-activated protein kinases and small GTPases. 13 Cell migration also requires focal adhesions that involve activation of the focal adhesion kinases. 14 These events take place in the cytoplasm, and there is recent intriguing evidence to suggest that early after growth factor induction, p27
Kip1 is shuttled out of the nucleus into the cytoplasm without further degradation, where it may carry out diverse functions. These hypotheses require testing in future studies.
The study by Sun et al 6 has tremendous clinical application. A major limitation of stent therapy is the development of a cellular response within the stent (ie, in-stent restenosis). Several promising approaches are in clinical investigation, including radiation. However, the development of a therapeutic modality that would reduce the potential toxicities of radiation would have great clinical appeal. Stents coated with antiproliferative and/or antimigratory agents, like sirolimus, are undergoing experimental clinical testing, and early results look very promising. 15 In addition to rapamycin, paclitaxelcoated stents also show considerable promise. 16 Paclitaxel disrupts microtubules within the cytoskeleton, also preventing cell migration. 17 We will eagerly await the results of phase II and III trials of both agents. In the future, one could imagine stent technology progressing from protein coatings to plasmid DNA coatings that might permit longer regulated expression of antiproliferative and/or antimigratory genes.
We now recognize that cell cycle proteins regulate multiple, diverse cellular functions in the cardiovascular system. These are proliferation, DNA damage and repair, and apoptosis; now, with the findings of Sun et al, migration can be added to the list. Studies such as the one by Sun et al 6 open up broad new areas for research into the molecular regulation of cell migration by signaling pathways "outward in" and Regulation of the cell cycle. Progression through G1 phase of the cell cycle occurs by the assembly and phosphorylation of cyclin and CDKs. The CKIs act as brakes to halt the cyclin and arrest cycles. PCNA indicates proliferating cell nuclear antigen; Rb, retinoblastoma; and P, phosphorylated.
"inward out." Importantly for our patients, the contributions of Sun et al 6 and others suggest dynamic new therapeutic applications for agents that modulate the cell cycle and its diverse functions for a variety of vascular diseases.
